OncoDNA has signed a subcontract service agreement with HalioDx's U.S.-based CLIA-certified laboratory in Richmond, VA. The agreement expands the France-based firm's reach to biopharmaceutical companies and research institutions in North America.
OncoDNA's products and services are already available in 50 countries. The firm's personalized cancer therapies are currently used in pan-European clinical trials and research projects, such as Kura Oncology's HRAS tipifarnib clinical study and the Aurora metastatic breast cancer research program.
